Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CV8102 + IMA970A |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CV8102 | CV 8102|CV-8102 | CV8102 is a non-coding RNA-based immune activator that stimulates TLR7/8 and RIG-I signaling and potentially increases antitumor immune response (PMID: 36319717). | ||
IMA970A | IMA-970A|IMA 970A | IMA970A is a cancer vaccine comprising 16 synthetic tumor-associated peptides (TUMAPs), which potentially induces anti-tumor HLA class I and II T-cell responses (PMID: 35421231). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|